Pharmaceutical PV DIV - FSB
Ended Awarded Last action
- Contract number
- SPE2DU26FENXV
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,730
Award facts
- Contract value 100% obligated
- $24,729.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $24,729.64 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order, issued on December 19, 2025, is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with a $499.9 billion ceiling value under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The delivery order represents no set-aside designation, indicating DMS Pharmaceutical Group competed on an unrestricted basis. DMS Pharmaceutical Group has been registered in the System for Award Management since July 2001 and serves as a critical supplier of pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
Under this delivery order and the broader PPV-G GEN V prime vendor contract awarded on November 13, 2025, DMS Pharmaceutical Group supplies a comprehensive range of products including branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support military medical operations. The PPV-G GEN V program is structured as a 30-month base period with three 30-month option periods extending through December 31, 2036, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors within the Defense Logistics Agency's broader $30.3 billion pharmaceutical acquisition strategy. The company's demonstrated performance across diverse therapeutic categories, including oncology treatments, immunosuppressants, emergency medications, and routine pharmaceuticals, establishes its capability to fulfill specialized pharmaceutical requirements for Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DU26FENXV?
SPE2DU26FENXV was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 19, 2025.
How much is contract SPE2DU26FENXV worth?
The government has obligated $24,730 on SPE2DU26FENXV.
Is contract SPE2DU26FENXV an order under another contract?
Yes. SPE2DU26FENXV is a delivery order under SPE2DU25D9418, an indefinite delivery contract.
Was contract SPE2DU26FENXV competed?
The extent of competition for SPE2DU26FENXV was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award